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Abstract
Background: Osteoarthritis (OA) is a chronic degenerative joint disease that is a clinically and economically important disease. The 
increased prevalence of OA with aging, coupled to the demographics of aging populations, make OA a high priority health care   problem. 
Viscosupplementation (VS) is a well-established treatment option in knee OA that is included in the professional guidelines for   treatment 
of this joint disease, and could potentially provide a useful alternative in treating such patients with painful OA. Theoretically VS is an 
approach that should apply to all synovial joints.
Objectives: The aim of this review is to assess the efficacy and safety of viscosupplementation with Hylan GF-20 (Synvisc®) in the 
management of joint pain in osteoarthritis.
Methods: The following databases were searched: Medline, Database of Abstract on Reviews and Effectiveness, Cochrane Database of 
Systematic Reviews. Furthermore, the lists of references of retrieved publications were manually checked for additional references. The 
search terms Review, Viscosupplementation, Osteoarthritis, Hyaluronic acid, Hyaluronan, Sodium Hyaluronate, Hylan GF-20, Synvisc, 
intra-articular injection were used to identify all studies relating to the use of Synvisc® viscosupplementation therapy in OA.
Results: Hylan GF-20 is a safe and effective treatment for decreasing pain and improving function in patients suffering from knee and 
hip OA but new evidences are emerging for its use in other joints.
Keywords: review, viscosupplementation, osteoarthritis, hyaluronic acid, hyaluronan, sodium hyaluronate, synvisc®, hylan GF-20, 
intra-articular injectionMigliore et al
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Introduction
Osteoarthritis is a chronic degenerative joint multi-
factorial disease. The disease process of osteoarthritis 
is characterised by the progressive destruction of the 
articular cartilage, leading to joint space narrowing, 
subchondral  sclerosis,    subchondral  cyst,  synovial 
inflammation  and  marginal    osteophyte  formation.1 
The progression of osteoarthritis leads to exposure of 
subchondral bone at a weight-  bearing site at which 
the bone will then be subjected to   abrasion and fur-
ther damage. The primary role of synovial fluid is 
protective, by means of limiting axial forces on the 
articular  surface  and  decreasing    friction  between 
joint  surfaces.  Hyaluronan  is  entirely  responsible 
for the elastoviscosity of synovial fluid. Because of 
its  hyaluronan  content,  synovial  fluid  can  behave 
as either a predominantly viscous fluid or a elastic 
  fluid.2 Hyaluronan is also responsible for   protecting 
the    collagen  fibrils  and  cells  of  articular  surfaces, 
  synovial tissue, capsule and ligaments from mechan-
ical damage.3 In osteoarthritis, the synovial fluid is 
more abundant and less viscous.4Hyaluronan becomes 
depolymerized,  its  concentration  and  molecular 
weight are decreased, resulting in a decrease in elas-
toviscosity. These changes increase the susceptibil-
ity of cartilage to injury.2,5,6 Osteoarthritic synovial 
fluid  functions  primarily  as  a  viscous  rather  than 
elastic fluid through the entire range of joint move-
ment, which reduces its protective effect on carti-
laginous, fibrous, and cellular structures. As articular 
cartilage is progressively damaged, the net rate of 
proteoglycan synthesis ultimately falls and the carti-
lage thins, resulting in a decrease in the load-bearing 
capacity.7 Administration  of  exogenus  Hyaluronan 
(HA) preparations addresses this problem by replac-
ing the low viscoelastic synovial fluid with solutions 
of higher viscosity.8 There are also substantial data 
that  exogenously  provided  HA  may  also  improve 
pain and function by non-mechanical, biologically 
based  mechanisms  within  the  synovial  and  articu-
lar environment.9 Current treatment options for OA 
include the use of simple analgesics or nonsteroidal 
anti-inflammatory  drugs  (NSAIDs),  intra-  articular 
(IA) corticosteroid injection, weight reduction and 
surgical treatment. Prior to surgical treatment of OA, 
which is expensive and not risk-free, all other treat-
ment options should be fully considered. VS with IA 
HA was approved by Food and Drug Administration 
(FDA) in 1997. VS is a well-established treatment 
option in knee OA and is included in the professional 
guidelines for treatment of the disease in this joint.10,11 
Theoretically VS is an approach that should apply to 
all synovial joints. A number of recent studies have 
attempted to   evaluate its efficacy in joints other than 
the knee. The   primary symptom of OA is pain that is 
seen as entirely linked with function, with physical 
movements triggering pain, while pain, in turn, causes 
limitations  in  physical  function.  To  cope,  patients 
will avoid certain movements and activities that they 
know will cause pain, and will engage in adaptive 
behavior to moderate the pain experience, such as 
organizing their homes to limit the need for move-
ments or positions that are more likely to be painful.12 
There are five injectable forms of HA approved by 
the United States FDA including Hyalgan®, Supartz®, 
Orthovisc®,   Synvisc®, and Euflexxa®. Each of these 
HA products differ in their origin, method of produc-
tion, molecular weight, dosing instructions, biologic 
characteristics, and possibly clinical outcomes. Hylan 
G-F 20 (Synvisc® Genzyme Corporation, Cambridge 
MA U.S.A.) is one of the VS products approved for 
marketing in Canada since 1992 and the United States 
since 1997 after public review of the data by a Food 
and  Drug  Administration  (FDA)  advisory  panel.13 
Hylan GF-20 is a high-molecular weight HA derivate 
composed of two hylan polymers within a buffered 
physiological  NaCl  solution.  The  phenomenon  of 
cross-linking (the first cross linking using formalde-
hyde and the second cross-linking forming sulfonyl-
bis-ethyl  cross-links  between  the  hydroxyl  groups 
of polymer chains) leads to the main characteristic 
of the product by the formation of a mixture of two 
different hylan polymers: hylan A (80%), which is a 
soluble high MW molecule (MW of 6.000.000 Da), 
hylan B (20%), which is an insoluble gel.14 The rheo-
logical properties of two forms of hylan are different 
from each other and both are significantly different 
from unmodified hyaluronan; the cross-linking also 
allows  a  longer  residence  time  into  the  joint  than 
that of linear HA products, in particular for hylan B, 
whose insolubility delays its removal from the joint. 
The IA residence time of hylan GF-20 has been stud-
ies in animal models.14 In rabbits, the estimated half-
life is 40 h and that of linear HA does not exceed 
24 h. Hylan GF-20 is non-immunogenic, non-inflam-
matory, and des not cause foreigh-body reaction. The Safety and efficacy of Synvisc® in osteoarthritis joint pain
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objective of this review is to assess the efficacy and 
safety of VS with Hylan GF-20 (Synvisc®) intra-ar-
ticular injections in the management of joint pain in 
osteoarthritis of the knee, hip, ankle, shoulder, tem-
poromandibular and thumb joint.
Inclusion Criteria
The following databases were searched: Medline, 
Database  of Abstract  on  Reviews  and  Effective-
ness,  Cochrane  Database  of  Systematic  Reviews. 
Furthermore,  the  lists  of  references  of  retrieved 
publications  were  manually  checked  for  addi-
tional references. The search terms Review, Visco-
supplementation,  Osteoarthritis,  Hyaluronic  acid, 
Hyaluronan,  Sodium  Hyaluronate,  Hylan  GF-20, 
Synvisc, intra-articular injection were used to iden-
tify all studies relating to the use of Synvisc® vis-
cosupplementation  therapy  in  OA.  The  search  of 
the literature performed in this study were limited 
to  published  original  studies  including  patients 
with a diagnosis of knee, hip, ankle, shoulder, basal 
joint and temporomandibular OA, made based on 
detailed clinical and radiographic information. All 
studies using Hylan GF-20 in treatment of OA in 
human  were  included.  Studies  comparing  Hylan 
GF-20 with different types of HA, treatments such 
as placebo, NSAIDs, corticosteroid injections, sup-
portive measures and other active treatments, were 
included.  Furthermore,  respect  the  studies  using 
Hylan GF-20 in treatment of knee OA we calculated 
the percentage of pain reduction from baseline to 
end of follow-up (Table 1 and Table 2).
Results
Clinical data in knee Oa
Hylan GF-20 vs. Placebo
Data in literature shows that Hylan GF-20 is effec-
tive and safe in relieving pain and increasing mobil-
ity in patients with chronic idiopatic OA of the knee. 
There  are  3  randomized  placebo  controlled  trials 
which  shows  efficacy  of  3  IA  injection  of  hylan 
GF-20  compared  to  placebo  at  8,15  1216  and  2617 
weeks. Only one transient local AE that not required 
treatment was reported by Scale et al16 systemic reac-
tion such as itching and calf cramps were reported 
by  Wobig  et  al17  in  three  hylan  GF-20-treated 
patients  but  none  of  these  required  treatment  or 
study discontinuation. Another RCT, performed by 
Chevalier et al18 shows that IA injection of another 
  formulation of hylan GF-20 with a volume of 6 mL 
syringe   (SynviscOne®) as unique injection is safe and 
  efficacious at 26 weeks. The efficacy and safety of a 
single 6 mL injection of hylan GF-20 was reported 
also by   Conrozier et al19 that performed a prospec-
tive, randomized trial   comparing different therapeutic 
regimens of hylan GF-20. This study suggests that a 
single 6 mL injection of hylan G-F 20 may be as effi-
cacious, and as well tolerated, as 3 × 2 mL one week 
apart. Two RCT compare the efficacy and safety of 
three products (Hylan GF-20, Artzal20 or Orthovisc21) 
versus placebo. In the first one20 the IA injections 
produced a significant improvement on all outcome 
measures after 26 weeks in all the groups. In direct 
comparison against placebo for weeks 0–52, neither 
hyaluronan treatment showed a significantly longer 
duration of clinical benefit than placebo. However, 
when  data  for  the  two  hyaluronan-treated  groups 
were pooled, treatment with hyaluronan had a sig-
nificantly longer duration of benefit compared with 
placebo (P = 0.047). No difference in AE between 
two groups were recordered. In the second trial,21 at 
the end of 6 months follow-up, the outcome mea-
sures were significantly better than baseline for both 
of the HA groups and remained significant until the 
end of 6 months. All groups expressed improvement 
with  physician  global  assessment  scores  after  the 
first injection; this improvement reached statistical 
significance at the third injection in favour of HA 
group and lasted until the end of 3 months. Although 
the placebo group seemed worse, this difference was 
not statistically significant.
Hylan vs. other HA derivated
Differences  of  efficacy  related  to  the  molecular 
weight and other characteristics of hyaluronans are 
under  discussion.  Several  RCT  evaluated  efficacy 
of    Synvisc  compared  with  low  molecular  weight 
Hyaluronan (Table 2). Juni et al22 assessed the com-
parative  efficacy  and  safety  of  three  viscosupple-
ments: hylan GF-20, a medium MW HA from avian 
sources (Orthovisc®) and a medium MW HA derived 
from bacterial sources (Ostenil®). 660 patients were 
randomly assigned to receive 1 cycle of 3 IA injec-
tion  of  these  3  preparations.  They  concluded  that 
no evidence was found for a difference in efficacy 
between hylan GF-20 and HA. Two AEs, 1 episode Migliore et al
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of  septic  arthritis  after  avian  HA  injection,  and  1 
episode of anaphylactic shock after hylan injection, 
were judged to be probably related to the treatment. 
Keratosan  et  al23  compared  the  long-term  effects 
of  three  intra-articular  injections  of  Synvisc®  or 
  Orthovisc® in patients with severe OA of the knee. 
In this trial both HA preparation shows a reduction 
in pain and improved function during a period of 52 
weeks without statistically significant differences. At 
the opposite, Raman et al24 demonstrated a significant 
superiority of Hylan GF-20 over Hyalgan®. Hylan 
acted more rapidly and with a more lasting effect of 
HA. No statisically significant difference in AE related 
to the treatment were reported. Other trials compared 
the effects of three intra-articular injections of high 
and low MW HA in patients with knee OA. Wobig 
et al25 showed a significantly better results on all pri-
mary outcome measures in the hylan group compared 
with those who received LMW HA. Atamaz et al26 
compared the effects of physical therapy agents like 
infrared, short-wave diathermy pulsed patterns and 
interferential therapy (PTA) versus Orthovisc® and 
Hylan GF-20. The results of this study support the 
PTA to be useful, safe and well-tolerated treatment, 
as well as hyaluronan therapy, but PTA includes some 
disadvantages: it is time wasting and its availability 
is conditioned on coming to the rehabilitation cen-
ter during consecutive 15 days. Moreover Compared 
with HA, hylan seems to be a more appropriate agent 
with its high molecular weight for some of the symp-
toms such as pain. Data obtained from these trials are 
conflicting. The conclusions of the Cochrane meta-
analysis presented seem to be in favour of a higher 
efficacy both on pain and function of Hylan G-F 20 
to any form of systemic intervention or intra-articular 
corticosteroids.27–29
Hylan vs. conventional terapies
Raynault et al30 conducted a prospective, random-
ized,  pragmatic  12-month,  healt  outcome  study 
in  255  patients  randomized  to  either  appropriate 
care (AC), alone or AC plus VS with hylan GF-20 
(AC+H). The AC+H group was superior to the AC 
group for all primary and secondary outcome mea-
sures. These differences were all statistically sig-
nificant and exceeded the 20% differences between 
groups  set  by  the  investigators  as  the  minimum 
clinically important difference. As OA is a chronic Migliore et al
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condition, the efficacy of repeated treatments is an 
important  consideration.  Several  trials  have  stud-
ied patients receiving up to eight course of VS and, 
overall,  found  that  efficacy  levels  are  maintained 
with repeated treatment.31,32 Paker et al33 in a RCT 
6-months follow-up, assessed and compared the effi-
cacy of TENS and IA Hylan GF- 20 in 60 patients 
with symptomatic knee OA. TENS was applied for 
3 weeks in the first group, and in the second group, 
hylan GF-20 was injected once a week for 3 weeks. 
The results of this study showed that these thera-
pies used in combination may alleviate symptoms in 
patients with OA.
Hylan vs. oral NSAIDs
Hylan GF-20 has been compared with continuous 
intake  of  NSAIDs  in  two  controlled  randomized 
multi-centre trials (Table 3). Adams et al34 compared 
VS  with  Hylan  GF-20  with  continuous  NSAID 
therapy. Hylan GF-20 was at least as effective for 
pain during motion as NSAID therapy at 12 weeks 
but was significantly better than NSAID therapy at 
26 weeks (P , 0.05). In a second prospective ran-
domized trial, performed by Kahan et al35 was com-
pared the medioeconomic beneficts over 9 months 
in 506 patients given Hylan GF-20 or conventional 
treatment. This study confirms that Synvisc® VS is 
more  effective  than  conventional  treatment,  at  no 
additional cost.
Table 3. RCT concerning viscosupplementation treatment vs. NSAIS.
study Year Trial patients Products Outcome 
measures
IA Inj Interval Follow up Statistic 
results
Adams 
(34)
1995 RCT 102 NSAID 
Hylan GF-20 
Hylan 
GF-20+NSAID
wBP 
NP 
RP 
RA
3 1 w 12–26 w Neg 
Neg 
P = 0.05 (Hylan) 
Neg 
P , 0.05 (H+N vs. N) 
P , 0.05 (H+N vs. N, vs. H) 
P , 0.05 (H+N vs. N, vs. H) 
P , 0.05 (H+N vs. N)
Kahan 
(35)
2002 RCT 506 Hylan GF-20 
conventional 
treatment
Lequesne 
wOMAC 
SF12 
wP 
Medical  
Costs
3 1 9 m P , 0.0001 
P , 0.0001 
P , 0.0001 
P , 0.0001 
Neg
Abbreviations: wBP, weight-bearing pain; NP, night pain; RP, pain at rest; RA, restriction activity; PFw, pain during a 50 foot walk; wP, walking pain.
Hylan vs. CCS
Results  from  randomized  controlled  trials36,37 
  comparing Hylan GF-20 to intra-articular corticos-
teroids,  including  a  total  of  318  patients,  showed 
  controversial results (Table 4). Caborn et al36 reported 
a 26-week, single-blind RCT comparing three weekly 
injections of Hylan G-F 20 to one IA injection of tri-
amcinolone hexacetonide in 218 patients with knee 
OA. Treatment with Hylan G-F 20 showed a longer 
duration of effect than triamcinolone hexacetonide. 
Both  treatments  were  well  tolerated  with  10%  of 
patients  in  each  group  reporting  an  adverse  event 
that resulted in withdrawal from the trial. These data 
support the preferential use of HG-F 20 over TH for 
treatment of chronic OA knee pain. Leopold et al37 
  performed a randomized controlled trial   comparing 
three weekly injections of Hylan G-F 20 to one IA 
injection of betamethasone sodium phosphate in which 
no   differences were detected between the two groups 
with respect to pain relief or function at six months 
of follow-up. In general patients treated with Hylan 
GF-20 experienced a grater improvement   sustained 
over  time  than  those  treated  with    intra-  articular 
  corticosteroids. IA corticosteroids injections seems to 
be more effective at the beginning but HA is better 
in terms of the duration of pain relief. Furthermore, 
a review of studies evaluating the use of corticos-
teroid injections show a lack of consensus regard-
ing their dosing and time course of   administration. Safety and efficacy of Synvisc® in osteoarthritis joint pain
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Among these reviews, we also observed that confu-
sion often arises regarding dosing when making a 
direct   correlation between equivalences and relative 
potency of corticosteroids. This lack of uniform injec-
tion guidelines is important because deleterious con-
sequences, both systemic and local, can result from 
corticosteroid injections, especially from chronic use, 
large doses, and errant injection.
Clinical Data in Others Joints  
than Knee
Theoretically  viscosupplementation  is  an  approach 
that  should  apply  to  all  synovial  joints.  Starting 
from 2006 Synvisc® is also approved in European 
  countries for ankle and shoulder OA. Off-label use 
in    degenerative  arthritis  of  temporo-mandibular 
and    carpo-metacarpal  joint  of  the  thumb  seems  to 
be increasing and a number of recent studies have 
attempted to evaluate its efficacy in joints other than 
the knee and the hip.
Clinical data in hip OA
Conrozier  et  al38,39  in  two  pilot  study  without 
  control group, suggest that Hylan GF-20 could be 
a  symptomatic  treatment  for  hip  OA,  particularly 
in less severe radiological cases. The percentage of 
“responder”  patients  according  to  the  OMERACT 
OARSI  criteria  gives  an  indication  of  the  poten-
tial benefit of this treatment as more than 50% of 
patients fulfilled the response criteria 90 days after 
the fluoroscopic guided injection. Transient hip pain 
was reported following 10.1% of injections, but no 
patients  withdrew  from  the  study  because  of  this. 
Two mild synovial fluid aseptic effusions occurred 
after the first injection.
In  three  prospective  open  label  study  1-year, 
3-months and 6-moths follow-up, performed respec-
tively by Vad et al40 Caglar Yagci et al41 and Brocq 
et al42 was showed that IA injections of Hylan GF-20 
under fluoroscopic guidance is a viable option for 
treatment of mild to moderate OA of the hip joint. 
No complications related to the injection40,41 and a 
self-limited exacerbation of pain during the first few 
days in three patients were observed.42 In the study 
of Vad et al 40 twenty-two patients who had failed 
to find pain relief from conservative methods were 
injected  with  2  mL  of  Hylan  GF-20  at  2,  3,  and 
4 weeks and a fluoroscopic lavage with 100 mL of 
normal saline was performed at week 1. All patients 
had standard hip exercise regimen after the injection. 
At 1-year follow-up, the AAOS (American Academy 
of Orthopaedic Surgeons) Lower Limb Core Scale 
score improved from a pre-injection mean of 44.2 to 
a follow-up mean of 86.1 (P = 0.05). The mean visual 
numeric pain score improved from a pre-injection 
mean of 8.7 (range, 6.4–10) to a follow-up mean of 
2.3 (range, 0–7.2). The overall success rate was 84%. 
In patients with mild to moderate OA, the mean pain 
score decreased from a pre-injection value of 7.8 to a 
follow-up value of 1.7. The   success rate was 90.5% in 
that subgroup. In patients with severe OA, the mean 
pain score decreased from a pre-injection value of 9.1 
to a follow-up value of 3.8. The success rate was 50% 
in that subgroup. Caglar et al41   established that, after 
three weekly hip   injections with Hylan GF-20, at the 
30th and 90th days of treatment, VAS, Lequesne hip 
Table 4. RCT concerning viscosupplementation treatment vs. corticosteroids.
study Year Trial patients Products Outcome  
measures
IA Inj Interval Follow up Statistic 
results
Caborn  
(36)
2004 RCT 218 Hylan GF-20 
Triamcinolone 
hexacetonide 
wOMAC A1 
wOMAC  
Total score 
patient and  
investigator  
assessments (vAS)
3 
 
 
1
1 w 26 w P = 0.007 
P = 0.001 
P = 0.0001 
P , 0.0300
Leopold 
(37)
2003 RCT 100 Hylan GF-20 
Betamethasone 
sodium  
phosphate 
Knee Society  
clinical rating 
scale 
wOMAC 
vAS pain
3 
1 (±1)
1 w 6 m Neg 
Neg 
NegMigliore et al
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OA severity index, and 15-meter walking period were 
statistically significantly lower than the correspond-
ing values before treatment. This decrease continued 
after the 30th day and was consistent with the reduced 
need of analgesics at the 1st and 3rd months. Brocq 
et al42 performed one or two Hylan GF-20 injections 
each to 22 patients with OA of the hip under fluoro-
scopic guidance and defined the treatment response 
as a 50% decrease in the Lequesne score at day 30. 
The  response  rate  was  50%  (11/22)  after  the  first 
injection. Patients who failed to respond to the first 
injection received a second one on day 30. The cumu-
lative response rate was found to be 13/22, and short-
term  safety  was  reported  as  satisfactory.  Migliore 
et al43–48 published 6 original articles concerning the 
ultrasound guided IA injection of Hylan GF-20 in the 
treatment of symptomatic hip OA. In five prospec-
tive open uncontrolled studies with a follow-up of 
3,43 6,45 1244,47 and 18 months,46 Migliore et al found 
that after injections of Hylan GF-20 2 mL into the 
hip  joint,  the  Lequesne/Womac  index,  VAS  pain 
score and NSAID consumption showed a statistically 
significant reduction comparing to the baseline. The 
first 12-months post-marketing study44 assessed the 
safety and efficacy of Hylan GF-20 in a large cohort 
of 220 patients with symptomatic hip OA. Patients 
received a single 2 mL injection of Hylan GF-20, 
under ultrasound guidance,with optional-additional 
injection  at  3  month  interval  during  follow-up  if 
symptomatically appropriate. Patients were followed 
up for 12 months. Outcome measures were: Lequesne 
Index, patient evaluation of pain in target hip during 
the last week (VAS), NSAID intake, patient and phy-
sician global assessment of the target hip (VAS).
The treatment provides a statistically   significant 
improvement in all the outcome measures (P , 0.05). 
These clinical improvement occurred as soon as the 
third month after treatment and were maintained for 
up to 12 months. NSAID intake reduced significantly 
after treatment and maintained significant to end of 
the study. Treatment was well tolerated despite the 
high mean age of the cohort and the co-morbidities of 
some patients. No AEs were recorded. Only mild and 
transient local adverse event were observed. Rennes-
son-Rey et al49 performed an open-label,   prospective 
trial, 6-months follow-up, to evaluate the influence 
of a joint effusion on the clinical response to a single 
injection of Hylan GF-20, fluoroscopic guided, in 
55 patients affected by hip OA. The   conclusion of 
the Authors was that the presence of a joint effusion 
is associated with worse pain and functional impair-
ment at baseline but has no influence on the clini-
cal response to Hylan GF-20 in patients with hip 
osteoarthritis. No AEs were recorded. Tikiz et al50 
performed a RCT in which the efficacy of IA injec-
tions of a LMW HA (Ostenil®) versus Hylan G-F 20 
(Synvisc®) in 43 patients with hip OA was compared. 
The  IA  injections,  performed  under  fluoroscopic 
guidance, produced a significant reduction in pain 
VAS, WOMAC and Lequesne index scores without 
significant differences in outcome between the two 
products. In the study of Van den Bekerom et al51 
120 patients, candidate for surgical treatment with a 
total hip arthroplasty, received VS with one of three   
hyaluronate formulations: Adant® (Group 1) LMW, 
Synocrom® (Group 2) LMW and Synvisc® (Group 3) 
HMW. Patients were assessed 6 weeks after each 
infiltration, performed under fluoroscopic guidance. 
VAS and Harris Hip Score (HHS) increased signifi-
cantly in groups 1 and 2 compared to baseline, but no 
statistical significant difference was noted between 
the groups. The Synvisc® group never reached statis-
tical significance in HHS and VAS during walk test 
after treatment, possibility due to the small number 
of patients (n = 15) in this group. The results of this 
trial should be considered in the light of the lim-
itations of the design study, that is a non placebo 
  controlled non randomized prospective study.
Clinical data in ankle OA
Luciani et al52 performed a prospective clinical trial 
with an 18-months follow-up in which 3 three weekly 
IA injections Hylan GF-20 2 mL was   performed   without 
any instrumental guidance in 21 patients affected by 
ankle OA. The primary   outcome measure was the 
ankle osteoarthritis score (AOS), that includes nine 
items on a pain sub scale (AOS-A) and nine items on a 
disability sub scale (AOS-B) and VAS scale. Regard-
ing pain (AOS-A) the improvement was statistically 
significant at the 12 and 18 month follow-up if com-
pared with   baseline (P , 0.05). Regarding disability 
(AOS-B) the improvement reached significance at the 
6-month follow-up and over time until the 18-month 
follow-up (P , 0.001). Also for pain assessed with 
VAS  scale,  a  similar  trend  was  observed,  with  a 
step decrease over the first 6 months (P , 0.0005). Safety and efficacy of Synvisc® in osteoarthritis joint pain
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This reduction remained significant at the 18-month 
  follow-up. In the prospective   multicenter open study 
of Witteveen  et  al53  55  patients  with  symptomatic 
ankle OA, were treated with IA injection of Hylan 
GF-20  2  mL,  without  any  instrumental  guidance, 
plus an optional second injection if pain remained at 
  baseline level after 1, 2 or 3 months, with 6–9-months 
follow-up period. The primary efficacy endpoint was 
the change from baseline in the patient-completed 
Study Ankle OA Pain VAS Score at 3 months. There 
was a statistically significant decrease in the mean 
score  of  the  patient-completed  Study  Ankle  OA 
Pain VAS from 68.0 mm at baseline to 33.8 mm at 
month 3 (P , 0.001). 31 patients received one intra-
  articular injection, and they had a mean change in 
VAS Score of -42.5 mm (P , 0.001); 24 patient 
who received two injections had a mean change in 
VAS Score of -23.5 mm (P , 0.001). The secondary 
efficacy endpoints were the change from baseline in: 
the total Ankle OA scale score, the patients’ global 
OA Assessment VAS score, the physicians’ global 
OA Assessment VAS score, the health related qual-
ity of life (SF-36). For all these endpoints, after the 
last injection, patients showed statistically significant 
improvement.   Carpenter et al54 performed a clinical 
trial, 13-months follow-up, in which the efficacy of 
ankle arthroscopy alone (AAA) versus ankle arthros-
copy combined with weekly IA injection of Hylan 
GF-20 2 mL (AA+H) during the first three postop-
erative weeks, was compared in 26 patients affected 
by ankle OA. Injection was blindly performed and 
without any instrumental guide. For the AAA group, 
the  median  and  interquartile  range  for  the  pre-
  intervention pain score was 8 (7.5, 9.5), whereas that 
for the post-intervention score was 3 (2, 3.5), and this 
difference was statistically   significant (P = 0.002). For 
the AA+H group, the median and interquartile range 
for the pre-intervention pain score was 9 (8, 9), and 
that for the post-intervention pain score was 1 (0, 2), 
and this difference was highly statistically significant 
(P = 0.0009).The median and interquartile range for 
the post-intervention pain score for the AAA group 
was 3 (2, 3.5); whereas that for the AA+H group 
was 1 (0, 2), and this difference was statistically sig-
nificant (P = 0.0002). The median and interquartile 
range for the reduction in pain for the AAA group 
was 5.5 (5, 6); whereas that for the AA+H group 
was 7.5 (6, 9), and this   difference was   statistically 
  significant  (P  =  0.0014).  Both  treatment  groups 
experienced statistically significantly decreased pain 
following  the  intervention,  and  patients  receiving 
three IA injections of Hylan G-F 20 following ankle 
arthroscopy improved statistically significantly more 
than arthroscopy group as a sole therapy. None of 
the totality of patients displayed any type of local or 
  systemic adverse events.
Clinical data in shoulder OA
Noel  et  al55  performed  an  open-label,  prospective, 
multicenter study in 33 patients with shoulder OA 
and an intact rotator cuff, to evaluate the feasibility, 
safety, and symptomatic efficacy of one or two IA 
Hylan GF-20 performed under fluoroscopic guidance. 
All the outcome measures (VAS pain score change 
between the baseline visit and 3 months after the last 
injection, VAS pain score differences between the last 
injection and each of the subsequent visits, the VAS 
pain score change between baseline and study com-
pletion, changes in shoulder stiffness and function as 
evaluated using the WOOS score, changes in the SF36 
quality-of-life score, and the patient and physician 
100 mm VAS scale scores for shoulder osteoarthritis 
related discomfort) showed significantly decrease at 
3 months after the last injection. 33 patients received 
a first injection. A second injection was performed in 
16 patients, after 1 (n = 7), 2 (n = 4), or 3 (n = 5) 
months. The VAS pain score decreased significantly, 
from 61.2 mm at baseline to 37.1 mm 3 months after 
the  last  injection  (P  ,  0.001).  The  mean  WOOS 
score  was  45.7%  at  baseline,  61.7%  after  7  days 
(P  ,  0.001),  63.1%  after  3  months  (P  ,  0.001), 
and 62.4% (P = 0.008) after 6 months. The mean 
SF-36 score was 38.6 points at baseline, 40.7 points 
after  3  months  (P  =  0.069),  and  43.3  points  after 
6 months (P = 0.007). The mean patient VAS discom-
fort score decreased from 55.7 at baseline to 36.3 mm 
after 3 months (P , 0.001), and the mean physician 
VAS discomfort score decreased from 59.6 mm at 
baseline to 35.7 mm after 3 months (P , 0.001). In the 
overall population, the proportion of responders was 
greatest after 2 months (20/29, 60.6%) and decreased 
slightly thereafter (54.5% after 3 months and 51.6% 
after 6 months). The response rates were higher in the 
subgroup of patients who required a single injection 
  (better immediate response): 70.6% after 3 months 
and  64.7%  after  6  months,    compared  to  37.5  and Migliore et al
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35.7% in the subgroup of patients who required two 
  injections.No AEs were reported   during the study. 
Only  eight  patients  reported  local  adverse  events. 
Also a   case-series study,  performed by   Silverstein 
et al56 evaluating the effects of 3 IA weekly injections 
of Hylan GF-20 2 mL in 30 patients with symptom-
atic glenohumeral OA who had failed 6 months of 
  conservative treatment, showed a significant improve-
ment in VAS pain, UCLA score and Simple Shoulder 
Test (SST) at the 6-month follow-up. The mean VAS 
score showed a significant reduction from baseline to 
1, 3, and 6 months after treatment (P = 0.01).
The mean modified UCLA scores improved from 
baseline at 1, 3, and 6 months after treatment with 
a statistically significance (P , 0.001). When the 
changes in individual scores were analyzed   compared 
with  baseline,  pain  (2.3-point  improvement)  and 
function (1.8-point improvement) were found to be 
both statistically (P , 0.001) and clinically signif-
icant. At baseline, the mean SST score was 5.7 of 
12 “yes” responses. Mean “yes” responses signifi-
cantly increased at 1 (P = 0.012), 3 (P = 0.001), and 
6 months (P = 0.001) after the third injection. When 
the SST score was evaluated in patients with a clini-
cally significant improvement in VAS ($20 points), 
the score improved from 5.7 at baseline to 8.7 of 
12 “yes” responses at 6 months. In those for whom 
the VAS improvement was , 20 points, the SST 
increased for 5.7 at baseline to 6.4 at 6 months. The 
number  of  patients  who  could  sleep  comfortably 
without any interference from their arthritic shoul-
der significantly increased (P # 0.001) from base-
line (n = 4) to the 1, 3, and 6-month visits. These 
data support the beneficial role of Hylan GF-20 in 
some  symptomatic  patients  with  glenohumeral 
osteoarthritis.
Clinical data in TMJ OA
The case-series of Yustin et al57 was one of the first 
that reported the use of 1 mL of hylan GF-20 by IA 
injection to manage TMJ OA and their patient func-
tioned well and felt comfortable for 4 months after 
3  Injections.  Møystad  et  al58  performed  a  RCT  to 
  compare the bone changes in the TMJ, assessed on 
computed  tomography  (CT)  examinations,  before 
and  after  2  IA TMJ  injections  of  hylan  GF-20  or 
  Celestone    Chronodose,  in  patients  with  TMJ  OA. 
Thirty-six  patients  were  radiographically  re-exam-
ined with high resolution CT after 6 months. There 
were no statistically significant differences between 
the 2 study groups with regard to any of the variables 
and to the averaged score of any of the Osteoarthritic 
signs. This study shows that both progression and 
regression of radiographic bones changes might occur 
in the TMJ after injection of Hylan GF-20 or corti-
costeroid after a short-term observation of 6 months. 
Yeung et al59 showed a statistically significant reduc-
tion of pain intensity and improvement in the maxi-
mum mouth opening parameter, after 2 IA injection 
of Hylan GF-20 2 mL in 27 patients with a MRI-con-
firmed diagnosis of non-reducing displacement of the 
TMJ disc who does not respond to conservative treat-
ment. No AE were registered. Yeung et al60 performed 
also a preliminary report to establish a protocol for 
image-guided minimally invasive surgical access to 
the TMJ. Axial MRI of the TMJ was obtained and 
loaded into an intra-operative navigation system to 
guide joint space injection. With the assistance of an 
intra-operative  navigational  system,  the  TMJ  MRI 
images were visualized in 3 dimensions and enabled 
guiding a needle into the superior and inferior joint 
spaces for therapeutic injection. The treatment out-
come for both patients was satisfactory with improve-
ment in pain score and mandible motion.
Clinical data in thumb OA
Heyworth et al61 compared IA hylan,   corticosteroid, 
and  placebo  injections  with  regard  to  pain  relief, 
strength,  symptom  improvement,  and  metrics  of 
  manual  function  in  sixty  patients  with  1st  CMC 
OA. The  Hylan  group  received  2  IA  injections  of 
Hylan  GF-20  1  mL  one  week  apart;  the  steroid 
group 1 mL placebo injection of normal saline and a 
1 mL of sodium betamethasone sodium phosphate– 
betamethasone  acetate  (Celestone  Soluspan)  1 
week later; the placebo group two IA injection of 
normal saline 1 mL one week apart. No statistically 
  significant  differences  were  observed  among  the 
three products for most of the outcome measures at 
any of the follow-up time points. However, based on 
the durable relief of pain, improved grip strength, and 
the long-term improvement in symptoms compared 
with   pre-injection   values, Authors suggest that hylan 
injections should be considered in the management 
of basal joint arthritis of the thumb. Figen Ayhan F. 
et al62 performed a RCT to evaluate the efficacy of Safety and efficacy of Synvisc® in osteoarthritis joint pain
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Hylan GF-20 on pain, function, and pinch strength 
for 6 months follow-up period in 33 patients with 
bilateral thumb base OA (1st CMC OA). A total of 
1 mL of Hylan G-F20 was injected to one trapezio-
metacarpal joint and 1 mL saline injection was made to 
contra-lateral joint.   Statistically significant improve-
ments were detected in function (P = 0.02) , VAS pain 
(P = 0.02), and pinch strength (P = 0.002) at the 24th 
week in the Hylan GF-20 group. However, only VAS 
pain scores decreased temporarily in control hands at 
the 6th week. Mandl et al63 performed a prospective 
open-label study to investigates if 3 repeated injections 
of Hylan GF-20 1 mL would relieve pain and improve 
function  in  patients  with  CMC  OA. At  26  weeks, 
mean VAS pain and DASH scores had improved sig-
nificantly. Both the DASH and VAS for pain were 
significantly  improved  over  baseline  at  26  weeks. 
A DASH change of 10–14 is considered clinically 
meaningful. At 26 weeks the mean change in DASH 
was 12.6, (SD 17.2) and the mean change in VAS for 
pain was 15.2 mm, (SD 29.5). VAS scores for pain 
at 26 weeks were moderately correlated with patient 
satisfaction (Spearman r = 0.52, P-value , 0.01), but 
were not correlated with hand strength, as measured 
by opposition and key grip. Although DASH scores 
at 26 weeks were significantly correlated with hand 
strength at 26 weeks, DASH scores showed no corre-
lation with patient satisfaction. Adverse events poten-
tially related to the injections included three episodes 
of post-injection pain and swelling, and one case of 
pseudogout.
Discussion
Despite the increasing morbidity of pain and func-
tional impairment, standard therapies for OA have 
not  progressed  over  the  past  few  years.  Standard 
therapies currently include the use of corticosteroids 
or NSAID despite evidence of increased frequency 
and severity of adverse effects and associated mor-
bidity, particularly in elderly patients. Hylan G-F 20 
is comparable in efficacy to IA corticosteroid that has 
a faster onset of action but a shorter duration of action 
than Hylan. In addition, repeated use of hylan is safer 
than  corticosteroids  in  patients  with  comorbidity 
such as corticosteroids are contraindicated. Several 
studies have shown a significantly reduced NSAIDs 
intake in both hip and knee OA after Hylan GF-20 
treatment; it was maintained significant for a long 
time. Moreover to evidence the improvement in pain 
management, the benefits of a reduction in the direct 
and indirect costs related to chronic NSAIDs use are 
obvious. In these days of heath economic evaluation 
of therapy options it is appropriate to consider this 
opportunity in the overall management of hip OA. 
Within this context, a correct evaluation of the role of 
Hylan GF-20 in the overall management of OA seems 
appropriate and in particular it seems to be a safe and 
effective treatment for decreasing pain and improving 
function in patients suffering from osteoarthritis. As 
OA is a chronic condition, the efficacy of repeated 
treatments is an important consideration. Several tri-
als have studied patients receiving repeated courses of 
Hylan GF-20 and, overall, found that efficacy levels 
are maintained with repeated treatment both in knee 
and hip OA.15–19,24–51
The  range  of  reduction  in  symptoms  and  pain 
seems to fluctuate in the various studies that evaluate 
the efficacy of Hylan GF-20 vs. LWM or vs. placebo 
in knee OA between 30 and 20% depending on the 
study and endpoint. Whereas this range, is understand-
able that some of these RCTs showed no statistically 
significant difference. In addition to establish a sta-
tistically significant difference between two different 
hyaluronic acid the sample size should be very high 
and this would lead to cost too high. Several studies 
have shown a significantly reduced NSAIDs intake in 
both hip and knee OA after Hylan GF-20 treatment; it 
was maintained significant for a long time. Moreover 
to evidence the improvement in pain management, 
the benefits of a reduction in the direct and indirect 
costs related to chronic NSAIDs use are obvious. In 
these days of heath economic evaluation of therapy 
options it is appropriate to consider this opportunity 
in the overall management of hip OA.
The dose given is different for each joint. Is well 
known for knee and hip joint (3 weekly injections of 
2 mL or one of 6 mL in knee OA and one   injection 
of 2 mL every six months, repeatable till every three 
months if clinically necessary, in hip OA). On the 
contrary  volume  and  scheduling  for  MCF,  ankle 
and shoulder is not clearly defined. In these reported 
studies it ranges from 1 mL to 2 mL for MCF, which is 
a small joint and 2 mL for ankle and shoulder joint.
In the European package insert is reported that 
Hylan GF-20 used in the treatment of hip OA should 
be  carry  out  under  image-guidance  (Fluoroscopy, Migliore et al
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TC or US). The use of ultrasound guidance ensures 
the accurate placement of Hylan GF-20 in the artic-
ular  space. The  ultrasound  guidance  is  faster  and 
cheaper than X ray, which are used in fluoroscopy 
and CT, and does not required the use of contrast. 
Additionally, ultrasonography can be repeated with-
out the problems associated with radiation load for 
both patient and operator. The use of US guidance 
may help to avoid the possible side effects of blind 
injections into difficult joint, especially for the hip. 
Direct evidence of the needle placement and direct 
evidence of the therapeutic fluid’s placement inside 
the joint space guarantee the efficacy and safety of 
the treatment.
In  recent  years  the  use  of  Hylan  GF-20  was 
extended to other joints offering new possibility in 
the treatment of OA. For instance shoulder OA is a 
common disorder resulting in pain, progressive loss of 
function, and diminished quality of life with limited 
treatment possibilities. The study of Noel55 suggests 
that injections of Hylan GF-20 may constitute a valid 
option specifically in patients with primary shoulder 
OA and an intact cuff. Also temporomandibular joint 
may be affected by OA, and in this case too, Hylan 
GF-20  seems  to  show  encouraging  results.  Data 
regarding use of Hylan GF-20 in hand and ankle OA 
appear to be promising. However further studies are 
necessary to clarify injecting volume, dosing regimen 
and outcome predictors.
The treatment with Hylan GF-20 is well tolerated 
in  all  joints  without  severe  systemic  AE.  Only 
2  case  series  reported  8  cases  of  granulomatous 
inflammation  after  three  intra-articular  injections 
of  Hylan  GF-20.64,65  In  these  case  reports  the 
granulomatous  inflammation  seems  to  have  been 
caused by the injected viscosupplementation   material. 
Histological  analysis  demonstrated    foreign-body 
granulomatous  inflammation  surrounding  acellular 
material in a palisading fashion. Moreover, it is not 
known whether the pathological agent   responsible 
is the hyaluronate derivative, a contaminant of the 
  purification  process,  or  a  component  of  the  car-
rier substance. Importantly, it appears that the syn-
ovial    granulomatous  inflammation  documented  in 
these  studies  represents  a  previously  unreported 
  pathological  response  to  a  viscosupplementation 
product,  which  should  raise  clinical  awareness  of 
this potential complication.   Further studies will be 
needed to demonstrate the real role played by Hylan 
GF-20    viscosupplementation  in  granulomatous 
inflammation of the treated joints. At present, this 
low incidence of side effects and the safety of Hylan 
GF-20 make it   particularly suitable in elderly patients 
who can’t   tolerate NSAID and   corticosteroids or in 
whom they are contraindicated. VS can also be used 
  concomitantly with other   therapies commonly used 
by elderly patients.
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